NI
Nanologica AB (publ)
NICA.ST · STO
0.35 kr -1.67% (-0.01 kr)
1M -21.85%
Market Cap 116.4M kr
P/E Ratio 6.20x
Div. Yield -
ROE 23.67%
Bulios Fair Price
0.41 kr
15.8% upside
Current Price
0.35 kr
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NICA.ST is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
93 /100
Cheap P/E 6.20x
P/B 0.74x
P/S 2.16x
Growth
78 /100
Growing Rev. growth 138.62%
Book val. growth 32.35%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 100.33%
FCF margin 108.41%
Net margin 34.87%
Quality
44 /100
Average ROIC 25.70%
Asset turnover 0.22x
ROE 23.67%
Debt
67 /100
Low Debt/Equity 0.34x
Int. coverage -12.88x
Current ratio 2.84x
Stability
30 /100
Unstable Beta -0.07x
Profitable years 0
Rev. volatility 513.60%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NICA.ST
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Andreas Bhagwani
Employees
19
Headquarters
Södertälje
Upcoming events
26 NOV
Earnings
Upcoming earnings report